TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6480458

Group type: EXPERIMENTAL
Intervention: Ro-03-8799 at 1 g/m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ro-03-8799
Number of subjects: 9
Study: 30580130

Group type: EXPERIMENTAL
Intervention: CSL112 6 g
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 30577848

Group type: EXPERIMENTAL
Intervention: Combined cycling and speed of processing training for 6 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cycling only for 6 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Speed of processing only for 6 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Attention control for 6 months
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 128
Study: 29771017

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids combined with normal saline nasal irrigation
Number of subjects: 273

Group type: COMPARATOR
Intervention: Intranasal corticosteroids only
Number of subjects: 273

Group type: COMPARATOR
Intervention: Intranasal corticosteroids combined with antihistamines
Number of subjects: 273
Study: 24727364

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT-AN)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Specialist supportive clinical management (SSCM)
Number of subjects: 63
Study: 22086310

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 599

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 599
Study: 19773728

Group type: COMPARATOR
Intervention: Transurethral Microwave Therapy (TUMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral Needle Ablation (TUNA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Holmium Laser Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transurethral Ethanol Ablation of Prostate (TEAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Intensity Frequency Ultrasound (HIFU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally Invasive Surgical Techniques (MISTs)
Number of subjects: 0
Study: 18991132

Group type: EXPERIMENTAL
Intervention: Attention deficit/hyperactivity disorder with comorbid conduct disorder and family functioning
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Conduct disorder in youth with high levels of hyperactivity symptoms, poor school functioning, and peer alcohol and drug use
Number of subjects: 217
Study: 16132387

Group type: COMPARATOR
Intervention: Cisplatin (Group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cisplatin, mitomycin, doxorubicin hydrochloride, and 5-fluorouracil (Group B)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cisplatin and TAE (Group C)
Number of subjects: 45
Study: 12608319

Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT) with verteporfin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10666802

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 30 mg/kg/day for 14 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin 100,000 IU/kg/day for 14 days
Number of subjects: 90
Study: 8848938

Group type: EXPERIMENTAL
Intervention: Diabetics (NIDDM patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diabetics with lacunar infarcts
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diabetics with normal MRI scans
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 40
Study: 2216203

Group type: EXPERIMENTAL
Intervention: Weekly membrane stripping beginning at 38 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (gentle cervicovaginal examination each week)
Number of subjects: 180
Study: 202160

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31741230

Group type: EXPERIMENTAL
Intervention: Biomarker-guided therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28775825

Group type: EXPERIMENTAL
Intervention: Left DLPFC anodal stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Right DLPFC anodal stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 25787680

Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel®, ConvaTec)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional gauze-based dressing
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel®, ConvaTec) and Conventional gauze-based dressing
Number of subjects: 80
Study: 23771714

Group type: EXPERIMENTAL
Intervention: Capecitabine plus paclitaxel (XP)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Epirubicin plus paclitaxel (EP)
Number of subjects: 340
Study: 21821865

Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 459

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 459
Study: 19288938

Group type: EXPERIMENTAL
Intervention: ESWL without JJ stent (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ESWL with JJ stent (Group B)
Number of subjects: 80
Study: 17373726

Group type: EXPERIMENTAL
Intervention: Levodopa therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard healthy population
Number of subjects: 5
Study: 15226168

Group type: EXPERIMENTAL
Intervention: Opuntia ficus indica (OFI) 1600 IU
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall symptom index with OFI
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Risk of severe hangover with OFI
Number of subjects: 64

Group type: COMPARATOR
Intervention: C-reactive protein levels after placebo
Number of subjects: 64
Study: 12169743

Group type: EXPERIMENTAL
Intervention: HFA aerosol inhaler
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dry Powder Inhalers (DPI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CFC inhaler
Number of subjects: 100
Study: 9683924

Group type: EXPERIMENTAL
Intervention: Angiotensin I (AngI) infusion at doses of 0.3, 1, and 3 pmol x kg‐1 x min‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II (AngII) infusion at doses of 0.3, 1, and 3 pmol x kg‐1 x min‐1
Number of subjects: 10
Study: 7706607

Group type: EXPERIMENTAL
Intervention: Protein-energy nutritional status
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Logistic regression model including serum albumin, body mass index, renal disease, Katz Index of Activities of Daily Living score, weight loss
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Logistic regression model tested on second sample of 110 patients
Number of subjects: 350
Study: 2785775

Group type: EXPERIMENTAL
Intervention: Immunotherapy with dog dander and hair extract (n = 35)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rush hyposensitization with dog dander and hair extract (n = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Conventional hyposensitization with dog dander and hair extract (n = 20)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Maintenance treatment (n = 15)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment (n = 12)
Number of subjects: 35
Study: 320062

Group type: EXPERIMENTAL
Intervention: Active chewing gum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 60
Study: 29852873

Group type: EXPERIMENTAL
Intervention: Patients with restenosis and the necessity of repeated revascularization
Number of subjects: 127

Group type: COMPARATOR
Intervention: Patients without restenosis
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 127

Group type: COMPARATOR
Intervention: Patients without diabetes
Number of subjects: 127
Study: 27836809

Group type: EXPERIMENTAL
Intervention: Hecolin vaccine (1 to 3 doses)
Number of subjects: 4273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4273
Study: 26515417

Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: clopidogrel
Number of subjects: 30

Group type: COMPARATOR
Intervention: no antiplatelet medication (controls)
Number of subjects: 30
Study: 23990163

Group type: EXPERIMENTAL
Intervention: Persistent albuminuria
Number of subjects: 2977

Group type: EXPERIMENTAL
Intervention: Progressive albuminuria
Number of subjects: 2977

Group type: COMPARATOR
Intervention: No albuminuria
Number of subjects: 2977

Group type: EXPERIMENTAL
Intervention: eGFR decline
Number of subjects: 2977

Group type: EXPERIMENTAL
Intervention: Verbal memory
Number of subjects: 2977
Study: 21769759

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19454355

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg daily) with lifestyle change
Number of subjects: 10198

Group type: COMPARATOR
Intervention: Control group (weight gain or no weight loss)
Number of subjects: 10198
Study: 16458640

Group type: EXPERIMENTAL
Intervention: 400 microg buccal misoprostol
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 15298564

Group type: EXPERIMENTAL
Intervention: 4 g fish oil capsules (containing 3.7 g n‐3 PUFA)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 4 g olive oil capsules
Number of subjects: 83
Study: 10653402

Group type: EXPERIMENTAL
Intervention: MP+PM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MP+H
Number of subjects: 150

Group type: COMPARATOR
Intervention: MP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CS+PM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CS+H
Number of subjects: 150

Group type: COMPARATOR
Intervention: CS
Number of subjects: 150
Study: 8656678

Group type: EXPERIMENTAL
Intervention: Low-dose all-trans retinoic acid (ATRA) at 15-20 mg/m2/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-dose all-trans retinoic acid (ATRA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: High-dose all-trans retinoic acid (ATRA)
Number of subjects: 27
Study: 2011425

Group type: EXPERIMENTAL
Intervention: High-frequency ventilation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 43
Study: 6807435

Group type: EXPERIMENTAL
Intervention: Sulpiride 50 mg thrice daily for four weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 28
Study: 31196068

Group type: EXPERIMENTAL
Intervention: Arclight ophthalmoscope (AO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: traditional device ophthalmoscope (TDO)
Number of subjects: 42
Study: 27017214

Group type: EXPERIMENTAL
Intervention: Robotic-assisted TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 60
Study: 25683252

Group type: EXPERIMENTAL
Intervention: Fathers for Change
Number of subjects: 18

Group type: COMPARATOR
Intervention: Individual Drug Counseling (IDC)
Number of subjects: 18
Study: 25422247

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia combined with SGB (0.12 mL/kg 1% lidocaine 10 min before induction)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (group N)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (SGB and control) during OLV
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (SGB and control) after OLV
Number of subjects: 40
Study: 22500884

Group type: EXPERIMENTAL
Intervention: Degarelix (240/80 mg)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Goserelin (3.6 mg) + Bicalutamide (50 mg for 28 days)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 182
Study: 19820073

Group type: EXPERIMENTAL
Intervention: Chest tubes < 10F
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Chest tubes 10-14F
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Chest tubes 15-20F
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Chest tubes > 20F
Number of subjects: 405

Group type: COMPARATOR
Intervention: Chest tubes of varying sizes
Number of subjects: 405
Study: 17623816

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg for 30 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15717868

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12063979

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alfa 2b (3 million international units intramuscularly three times a week for 4 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Not treated with interferon (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alfa 2b
Number of subjects: 46
Study: 10075323

Group type: EXPERIMENTAL
Intervention: Wood stanol ester-containing margarine (WSEM)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vegetable oil stanol ester-containing margarine (VOSEM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control margarine (no stanol esters)
Number of subjects: 55
Study: 9456718

Group type: EXPERIMENTAL
Intervention: Massage after exercise fatigue
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest after exercise fatigue
Number of subjects: 20
Study: 2910782

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cisplatin 50 mg/m2 over 24 hr
Number of subjects: 331

Group type: COMPARATOR
Intervention: Rapid infusion of cisplatin 50 mg/m2 at a rate of 1 mg/min
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 331
Study: 1161670

Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 78
Study: 26200522

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (Fe‐S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iron polymaltose complexes (Fe‐OH‐PM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined iron and zinc (Fe‐Zn)
Number of subjects: 60
Study: 28637670

Group type: EXPERIMENTAL
Intervention: GP2013 (biosimilar rituximab)
Number of subjects: 312

Group type: COMPARATOR
Intervention: RTX-EU
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: GP2013 and RTX
Number of subjects: 312
Study: 25873155

Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring for 6 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Blood pressure telemonitoring
Number of subjects: 55
Study: 24060993

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 14
Study: 21355145

Group type: EXPERIMENTAL
Intervention: Electroacupuncture on specific acupoints (Zhongji, Guilai, Yinlingquan, Sanyinjiao, Guanyuan, Shuidao, Xuehai, Taichong)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 47
Study: 19691631

Group type: EXPERIMENTAL
Intervention: Immediate removal of the polyp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 21778814

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16015688

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment after 6 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Primary biliary cirrhosis (PBC) patients (stages I and II)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chronic hepatitis C patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Viral HCV cirrhosis patients
Number of subjects: 52
Study: 12453861

Group type: EXPERIMENTAL
Intervention: IL‐2 9 MU subcutaneously twice daily on days 4‐8 and 25‐29, and once daily on days 11‐15 and 32‐36; IFN‐alpha‐2b 5 MU subcutaneously on days 1‐3 and then daily to day 43; Histamine 1 mg subcutaneously twice daily starting on day 4
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group receiving the same regimen without histamine
Number of subjects: 41
Study: 9658748

Group type: COMPARATOR
Intervention: Active ulcerative colitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active Crohn's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive inflammatory bowel disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical disease activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory parameters (C-reactive protein, leukocyte count)
Number of subjects: 0
Study: 7856295

Group type: EXPERIMENTAL
Intervention: Aerosol inactivated split influenza virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold-adapted reassortant live influenza virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mucosal administration of inactivated influenza virus vaccine
Number of subjects: 0
Study: 2536803

Group type: EXPERIMENTAL
Intervention: Two-hour infusion of cisplatin
Number of subjects: 22

Group type: COMPARATOR
Intervention: 24-hour infusion of cisplatin
Number of subjects: 22
Study: 1060146

Group type: EXPERIMENTAL
Intervention: Active immunotherapy after chemoradiotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no active immunotherapy)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immunotherapy after chemotherapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immunotherapy before chemotherapy
Number of subjects: 200
Study: 11473870

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 130/0.4, n = 21
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lactated Ringers solution (RL), n = 21
Number of subjects: 42
Study: 31315885

Group type: EXPERIMENTAL
Intervention: Repeated immunization with a Listeria monocytogenes‐based vaccine encoding for mesothelin in combination with a GM‐CSF‐transfected allogeneic pancreatic cell vaccine
Number of subjects: 0
Study: 29648860

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (B‐MI; n = 8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control treatment (1‐hour video; n = 10)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (B‐MI and control)
Number of subjects: 18
Study: 26304701

Group type: EXPERIMENTAL
Intervention: Nurse-led preoperative education
Number of subjects: 395

Group type: COMPARATOR
Intervention: Standard information by ward personnel
Number of subjects: 395
Study: 24615005

Group type: EXPERIMENTAL
Intervention: Confronting Approach
Number of subjects: 314

Group type: COMPARATOR
Intervention: Non-Confronting Approach
Number of subjects: 314
Study: 23070314

Group type: EXPERIMENTAL
Intervention: Global Processing Training (global-to-local encoding)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rote Repetition Training (no encoding strategy)
Number of subjects: 11
Study: 20416137

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) consisting of exposure and response prevention (EX/RP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Stress management training (SMT; an active CBT control)
Number of subjects: 108
Study: 18029964

Group type: EXPERIMENTAL
Intervention: Reiki intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional care control
Number of subjects: 32
Study: 16103696

Group type: EXPERIMENTAL
Intervention: Hand rubbing with alcohol-based solutions
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hand washing with antimicrobial soap
Number of subjects: 35
Study: 12482009

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program involving individualized health promotion by a research pharmacist with monthly appointments for 6 months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional care (control group).
Number of subjects: 100
Study: 9862651

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation (1 x 10^10 colony forming units/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 39
Study: 7657446

Group type: EXPERIMENTAL
Intervention: 4% nicotinamide gel
Number of subjects: 76

Group type: COMPARATOR
Intervention: 1% clindamycin gel
Number of subjects: 76
Study: 2697239

Group type: EXPERIMENTAL
Intervention: Labetalol 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Labetalol 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 972208

Group type: EXPERIMENTAL
Intervention: Behavioral contracting services offered at home and in school
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control condition with no behavioral contracting services
Number of subjects: 102
Study: 31543950

Group type: EXPERIMENTAL
Intervention: Menopausal hormone treatment (MHT) started within 5 to 10 years of menopause
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen treatment (ET) for women undergoing premature menopause
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menopausal hormone treatment (MHT) for normal women
Number of subjects: 0
Study: 28499728

Group type: EXPERIMENTAL
Intervention: Troponin push alerts to physician smartphones
Number of subjects: 1554

Group type: COMPARATOR
Intervention: No troponin push alerts
Number of subjects: 1554
Study: 26413574

Group type: EXPERIMENTAL
Intervention: 1500 mg/day Korean red ginseng for 4 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 3000 mg/day Korean red ginseng for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: 160 mg/day Ginkgo biloba extract for 4 weeks
Number of subjects: 61
Study: 23432431

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HSCT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 143
Study: 22077928

Group type: EXPERIMENTAL
Intervention: Soy isolate protein supplement (24 g daily for 8 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Milk protein supplement (24 g daily for 8 weeks)
Number of subjects: 90
Study: 19917449

Group type: EXPERIMENTAL
Intervention: Beta-glucan (5.5 g)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beta-glucan (2.2 g to 5.5 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Beta-glucan (various doses)
Number of subjects: 14